This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Fullgent Genetics (FLGT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Fullgent Genetics (FLGT) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is FULGENT GENETIC (FLGT) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of -0.78% and -21.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $110.87, marking a +0.33% move from the previous day.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
FULGENT GENETIC (FLGT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $92.25, marking a +0.36% move from the previous day.
Should You Invest in the SPDR S&P Health Care Services ETF (XHS)?
by Zacks Equity Research
Sector ETF report for XHS
FULGENT GENETIC (FLGT) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed the most recent trading day at $85.94, moving -0.13% from the previous trading session.
FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $87.17 in the latest trading session, marking a -0.31% move from the prior day.
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $83.53 in the latest trading session, marking a +1.17% move from the prior day.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $75.69, marking a +1.16% move from the previous day.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $84, marking a +0.1% move from the previous day.
FULGENT GENETIC (FLGT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 10.02% and 13.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed the most recent trading day at $73.01, moving +1.61% from the previous trading session.
What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?
by Zacks Equity Research
COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.
FULGENT GENETIC (FLGT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $87.64 in the latest trading session, marking a +0.52% move from the prior day.
FULGENT GENETIC (FLGT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $86.78 in the latest trading session, marking a -0.99% move from the prior day.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, FULGENT GENETIC (FLGT) closed at $88.95, marking a +1.37% move from the previous day.
FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) closed at $85.24 in the latest trading session, marking a -0.42% move from the prior day.
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day